Semaglutide Trial for Weight and Heart Risk in Young Adults With Type 1 Diabetes

Trial details

Who runs it

Yale University

Trial code

NCT06411210

Record updated

4 August 2026

Original description

More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and obesity.Read full original descriptionShow less

Obesity Complicating Type 1 Diabetes in Young Adults: Physiology and Impact of GLP-1 Analogue Anti-obesity Treatment on Cardiometabolic Risk Factors

More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and obesity.

Inclusion: Age 18-30 years with T1D whose BMI meets FDA approval criteria for anti-obesity pharmacotherapy (BMI ≥30 kg/m2 alone or BMI ≥27 kg/m2 with a weight-related comorbidity); Clinical diagnosis of T1D; Diabetes duration diagnosed ≥ 12 months ago; HbA1c ≤10% at screening and within the past 90 days; Stable reported insulin dosing in the past 90 days (within 15%); Stable reported BMI in the past 90 days (within 5%); Ability to provide written informed consent before any trial-related activities; Use of real-time continuous glucose monitoring and planned continued use; Females and males of childbearing potential willing to use highly effective methods of contraception for at least 1 month prior to randomization and agreement to use such a method during study participation and for 2 months after the last dose of study medication administration: Combined estrogen-progestogen contraception including: oral, intravaginal, transdermal (patch), Progestogen-only contraception: oral, injectable or implantable, Placement of an intrauterine device or intrauterine system, Bilateral tubal occlusion (fallopian tubes are blocked), Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate), or Complete sexual abstinence from male-female sex); Stated willingness to comply with all study procedures, medication regimen, and availability for the duration of the study; Participants cannot be randomized if any laboratory safety parameter at screening is outside the below extended laboratory ranges. For randomization, participants should have; Creatinine <1.0mg; Triglycerides (<400 mg/dl); ALT <3.5 times the upper normal limit (UNL).

Exclusion: Use of lipid lowering medications other than statins and omega-3 products; Previous randomization in this trial. Participants who enrolled but did not randomize can be re-screened. Potential reasons for enrolment without randomization include scheduling conflicts for the baseline studies, or for females, not yet meeting the highly effective methods of contraception criteria; Treatment with another investigational drug or other intervention within the past 1 month; Use of adjunctive diabetes therapies or anti-obesity medications (including any GLP-1 agonist) currently or within the past 6 months; Current psychiatric conditions impacting weight, including known eating disorders; Contraindications to study medications, including:; Personal history of pancreatitis, renal impairment, or known liver disease other than non-alcoholic hepatic steatosis; Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia Type 2; Known or suspected allergy to semaglutide, excipients, or related products; Subjects with a PHQ-9 score >15 or those found to have a lifetime history of suicide attempts, or suicidal ideation within the past 3 months on the C-SSRS; Corn allergy; Anemia or known hematologic condition impacting HbA1c reading, or another medical condition that precludes participation; Insulin dosing <0.5 units/kg/day; Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures; Diabetic ketoacidosis in the past 6 months; Not meeting MRI safety criteria or claustrophobia preventing participation in the MRI; Subjects with severe hypoglycemia requiring hospitalization in the past 3 months; Clinically significant gastroparesis.

ClinicalTrials.gov NCT06411210